deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT03293485

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

A Phase III Non-randomized, Non-controlled, Open Label Clinical Trial to Study the Safety and Efficacy of Imipenem/Cilastatin/Relebactam (IMI/REL [MK-7655A]) in Japanese Subjects With Complicated Intra-Abdominal Infection (cIAI) or Complicated Urinary Tract Infection (cUTI)

Sponsor: Merck Sharp & Dohme LLC

Updated 17 times since 2017 Last updated: Jan 20, 2021 Started: Oct 4, 2017 Primary completion: Sep 14, 2018 Completion: Sep 14, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Complicated Intra-abdominal Infection and Complicated Urinary Tract Infection, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 17 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Oct 2019 · 11 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2022 · 15 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

17 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Mar 2021 — Jun 2022 [monthly]

    Completed PHASE3

Show 12 earlier versions
  1. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE3

  2. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE3

  3. Oct 2019 — Nov 2019 [monthly]

    Completed PHASE3

  4. Nov 2018 — Oct 2019 [monthly]

    Completed PHASE3

    Status: RecruitingCompleted

  5. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  6. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  7. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  8. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  9. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  10. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

  11. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  12. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .